期刊文献+

恶性血液病并发第二肿瘤的临床特征与危险因素分析(附33例) 被引量:7

Clinical characteristics and risk factors analysis of patients with hematological malignancies associated with secondary primary malignancy( 33 cases)
下载PDF
导出
摘要 目的:探讨恶性血液病并发第二肿瘤患者的临床特征、可能的发病机制及危险因素分析。方法:收集自2013年1月至2017年4月于我院血液科就诊的33例罹患两种及以上恶性肿瘤(其中一种为血液系统肿瘤)患者的临床资料,对其进行回顾性分析。结果:33例患者中男性23例,女性10例,第二肿瘤中位发病年龄59岁,其中同时性多原发肿瘤6例,异时性多原发肿瘤27例,双重恶性血液病共8例,治疗相关性急性髓系白血病10例,三原发恶性肿瘤患者2例;33例患者中5例于院内死亡(病程7~12个月)。结论:多原发恶性肿瘤中以双原发、异时性恶性肿瘤多见;第二肿瘤中位发病年龄偏大,其确切病因及发病机制尚不明确,患者多有复杂染色体核型,预后不良;发生第二肿瘤的危险因素可能为第一肿瘤治疗史、吸烟史或特殊接触史(油漆、重金属铬、电子产品)。 Objective:To discuss the clinical characteristics and pathogenesis and risk factors of hematological malignancies associated with secondary primary malignancy.Methods:Collected the clinical data of 33 patients with more than two kinds of malignancy (one of which is hematological malignancy) from January 2013 to April 2017 in Department of Hematology,The First Affiliated Hospital of xi'anJiaotong University,and analyzed which retrospectively.Results:Among 33 cases,23 were male,10 were female,6 cases were synchronous malignancies while 27 cases were metachronous.8 cases were double hematological malignancies,10 cases were therapy-related acute myeloid leukemia,2 cases were triple tumors,5 cases died in the hospital (course were 7~12 month).Conclusion:Multiple primary tumors were more common in the patients with double primary tumors and metachronous malignancy.The median age of the SPM was relatively elder.The exact etiology and pathogenesis of SPM is not clear.These patients often have complex chromosome karyotype and poor prognosis.Risk factors for the occurrence of SPM may be the first cancer treatment history,smoking history or special contact history (paint,heavy metal chromium,electronic products).
作者 把环环 刘心 Ba Huanhuan;Liu Xin(Department of Hematology,First Affiliated Hospital of Xi'an Jiaotong University,Shaanxi Xi'an 710061,China)
出处 《现代肿瘤医学》 CAS 2018年第16期2610-2614,共5页 Journal of Modern Oncology
基金 西安交通大学第一附属医院临床研究中心科研基金资助项目(编号:2011YK.22)
关键词 多原发肿瘤 同时性 第二肿瘤 异时性 multiple primary malignant neoplasms synchronism secondary primary malignancy metachronism
  • 引文网络
  • 相关文献

参考文献1

二级参考文献13

  • 1VardimanJW, ThieleJ, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neo- plasms and acute leukemia: rationale and important changes[]]. Blood, 2009, 114(5) :937-951.
  • 2Deol A, Abrams J, Masood A, et al. Long-term follow up of pa- tients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML[J]. Bone Marrow Transplant, 2013, 48 (8) : 1112-1116.
  • 3Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associ- ations in 306 patients with therapy--related myelodysplasia and my- eloid leukemia: the University of Chicago series[J]. Blood, 2003, 102(1):43-52.
  • 4Kayser S, Dohner K, KrauterJ, et al. The impact of therapy-relat- ed acute myeloid leukemia (AML) on outcome in 2853 adult pa- tients with newly diagnosed AML[J]. Blood, 2011, 117(7):2137- 2145.
  • 5See HT, Thomas DA, Bueso-Ramos C, et al. Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with re- current ovarian cancer[J]. IntJ Gynecol Cancer, 2006, 16 Suppl 1: 236-240.
  • 6Takeyama K, Seto M, Uike N, et al. Therapy-related leukemia and myelodysplastic syndrome: A large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors[J]. In- ternational Journal of Hematology, 2000, 71(2):144-152.
  • 7Godley LA, Njiaju UO, Green M, et al. Treatment of therapy-re- lated myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant[J]. Leuk Lymphoma, 2010, 51 (6):995-1006.
  • 8Kroger N, Brand R, van Biezen A, et al. Risk factors for therapy-re lated myelodysplastic syndrome and acute myeloid leukemia treat ed with allogeneic stem cell transplantation[J]. Haematologica, 2009 94(4) :542-549.
  • 9Litzow MR, Tarima S, Perez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia[J]. Blood, 2010, 115(9):1850-1857.
  • 10Bally C, Thepot S, Quesnel B, et al. Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leuke- mia (tMDS/AML): a report on 54 patients by the Groupe Franco- phone Des Myelodysplasies (GFM)[J]. Leuk Res, 2013, 37(6):637- 640.

共引文献5

同被引文献49

引证文献7

二级引证文献7

;
使用帮助 返回顶部